Thermo Fisher Scientific’s New Spatial Imaging System Enables Researchers to Generate High-quality Data, Making it Easier to Enter the Field of Spatial Tissue Proteomics
WALTHAM, Mass. – Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Invitrogen™ EVOS™ S1000 Spatial Imaging System. This advanced system addresses the limitations of current fluorescent microscopy technologies by enabling researchers to generate a multiplexed high-quality image for multiple samples within several hours, thereby lowering the barrier to entry into spatial tissue proteomics.
“With the new EVOS S1000, we can select and utilize any antibody or reagent – allowing us more flexibility to choose the tools that best fit our research needs – or even work without antibodies, all of which reduces sample processing time”
The EVOS S1000, from Thermo Fisher Scientific’s innovative line of cell imaging microscopes and systems, leverages advanced and patented spectral technology, allowing researchers to capture images of up to 9 different targets simultaneously, which helps reduce the need for multiple rounds of imaging and preserves tissue integrity.
“Understanding tissue structure and function is crucial for developing new treatments for solid tumors and neurodegenerative diseases,” said Trisha Dowling, vice president and general manager for flow and imaging technologies at Thermo Fisher Scientific. “The EVOS S1000 delivers a detailed snapshot of tissue microenvironments and architecture in their native state, helping researchers accelerate their experiments, achieve more with their tissue samples and drive advancements in critical research areas.”
The system’s compatibility with a wide range of reagents and antibodies enables seamless integration into existing laboratory setups, helping meet the growing demand for multiplex imaging.
“Our lab handles everything from project design and sample preparation to imaging, and it’s critical that we deliver high-quality results to our customers, while also working to support our own research projects,” said Carolina Oses Sepúlveda, researcher and lab manager for spatial proteomics at SciLifeLab Stockholm. “With the new EVOS S1000, we can select and utilize any antibody or reagent – allowing us more flexibility to choose the tools that best fit our research needs – or even work without antibodies, all of which reduces sample processing time.”
Now commercially available in the United States and Europe, the EVOS S1000 Spatial Imaging System provides researchers with the tools they need to help advance the understanding of complex biological systems and develop new treatments for various diseases. For more information including technical specifications, applications and consumables please visit thermofisher.com/evoss1000
For research use only. Not for use in diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
